Device Trial Radar · NCT07770555
Deep Transcranial Magnetic Stimulation for Tobacco Cessation in Adults With Opioid Use Disorder
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Payel RoyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study will evaluate the use of deep transcranial magnetic stimulation (Deep TMS) to help adults with opioid use disorder (OUD) who are receiving medications for opioid use disorder (MOUD) such as buprenorphine or methadone and who continue to smoke cigarettes and want to quit. Deep TMS is a noninvasive form of brain stimulation that uses magnetic pulses. The BrainsWay Deep TMS System is cleared by the U.S. Food and Drug Administration (FDA) for smoking cessation. This study will use the H4 coil smoking-cessation protocol in people with OUD receiving MOUD. Approximately 12 participants will take part and all participants will receive active Deep TMS. There is no sham or placebo group and no random assignment. Participants may receive up to 18 Deep TMS sessions over 6 weeks: five sessions per week during the first 3 weeks, followed by one session per week during Weeks 4 through 6. Participants will return for a follow-up visit at Week 10. The main purpose of the study is to learn whether this Deep TMS approach is safe, tolerable and feasible for people with OUD receiving MOUD and to estimate how many participants are able to remain smoke-free from Week 6 through Week 10. The study will also look for early changes in tobacco craving, opioid craving, continuation of MOUD, mood and anxiety symptoms, pain, heart rate variability, and participants' experiences with the treatment. The findings will be used to help plan a larger future study.
Conditions
- Opioid Use Disorder
- Tobacco Use Disorder
Interventions
Deep TMS System With H4 CoilDevice
Active Deep TMS will be delivered using the Deep TMS System with the H4 coil according to the smoking-cessation protocol. Stimulation will be delivered at 120% of the participant's resting motor threshold, unless a protocol-approved modification is required, at 10 hertz (Hz) using 3-second trains, a 15-second inter-train interval, 60 trains, and 1,800 pulses per session. Each stimulation session lasts approximately 20 minutes. Participants may receive five sessions per week during Weeks 1 through 3, followed by one session per week during Weeks 4 through 6, for up to 18 sessions total.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Four-Week Continuous Smoking Abstinence (Continuous Quit Rate)Time frame: Weeks 6 through 10 (4-week abstinence window), with outcome determination at Week 10
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UPMC Presbyterian
Pittsburgh, Pennsylvania
University of Pittsburgh Medical Center (UPMC) Mercy - Internal Medicine Recovery Engagement Program (IM-REP)
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.